China Approves Clinical Trial of InnoCare Bispecific Antibody ICP-B161
InnoCare Pharma announced that China’s Center for Drug Evaluation approved a clinical trial of its bispecific antibody ICP-B161, which targets TL1A and IL-23p19.
Story updates
12:32:57 AM UTC
SquawkNews
InnoCare Pharma said China’s CDE approved its IND for ICP-B161, a long-acting bispecific antibody targeting TL1A and IL-23p19 for autoimmune diseases including IBD.Material DetailsContext by AI AnalystThis is an early-stage R&D milestone, adding another 2026 clinical start to InnoCare’s autoimmune…